<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04451772</url>
  </required_header>
  <id_info>
    <org_study_id>M20-186</org_study_id>
    <secondary_id>2020-001690-72</secondary_id>
    <nct_id>NCT04451772</nct_id>
  </id_info>
  <brief_title>A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State</brief_title>
  <official_title>A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation
      of multiple organ systems. This study will evaluate how well elsubrutinib and upadacitinib
      given alone or as the ABBV-599 combination (elsubrutinib/upadacitinib) works within the body,
      in participants who completed study M19-130. This study will assess the change in disease
      symptoms.

      ABBV-599 is an investigational drug being developed for the treatment of Systemic Lupus
      Erythematosus (SLE). This study is &quot;double-blinded&quot;, which means that neither the trial
      participants nor the study doctors will know who will be given which study drug. Study
      doctors put the participants into 1 of 4 groups called treatment arms. Each group receives a
      different treatment. Adult participants with a diagnosis of SLE will be enrolled. Around 260
      participants will be enrolled in the study in approximately 146 sites worldwide.

      Participants will receive the following for up to 56 weeks:

      Participants will receive oral elsubrutinib capsules or oral upadacitinib tablets once daily
      for up to 56 weeks. Participants who were receiving elsubrutinib and/or upadacitnib in
      M19-130 will continue to receive the same treatment in this study. Participants who were
      receiving placebo in M19-130 will be re-randomized to one of the 4 treatment arms in this
      study.

      Arm 1: Elsubrutinib Dose A and Upadacitinib Dose A Arm 2: Elsubrutinib Dose A and
      Upadacitinib Dose B Arm 3: Elsubrutinib Dose A and Upadacitinib Placebo Arm 4: Elsubrutinib
      Placebo and Upadacitinib Dose A

      There may be higher burden for participants in this trial compared to their standard of care.
      Participants will attend monthly visits during the course of the study at a hospital or
      clinic. The effect of the treatment will be checked by medical assessments, blood tests,
      checking for side effects and completing questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2020</start_date>
  <completion_date type="Anticipated">May 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Through Week 108</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Lupus Erythematosus Responder Index (SRI)-4</measure>
    <time_frame>Through Week 104</time_frame>
    <description>SRI is a composite responder index based on improvement in disease activity without worsening of the overall condition or the development of significant disease activity in new organ systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>British Isles Lupus Assessment Group (BILAG)-Based Combined Lupus Assessment (BICLA)</measure>
    <time_frame>Through Week 104</time_frame>
    <description>BICLA is a composite responder index based on improvement in organ systems without worsening of the overall condition and improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lupus Low Disease Activity State (LLDAS)</measure>
    <time_frame>Through Week 104</time_frame>
    <description>A state of low disease activity based on SLEDAI score (SLEDAI-2K score ≤ 4 excluding SLEDAI-2K activity in major organ systems), absence of systemic lupus erythematosus (SLE) disease activity in major organ systems and new disease activity, Physician's Global Assessment (PhGA) ≤ 1, and concomitant medication usage (steroid dose ≤ 7.5 mg QD and toleration of immunosuppressive drugs at standard maintenance doses).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Greater Than or Equal to ≥ 4-Point to 4-Point Decrease in SLE Disease Activity Index (SLEDAI)-2K</measure>
    <time_frame>Baseline of M19-130 (Week 0) Through Week 104</time_frame>
    <description>SLEDAI-2K is global SLE disease activity index that focuses on high-impact disease manifestations across the organ systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Steroid Burden</measure>
    <time_frame>Baseline of M19-130 (Week 0) Through Week 104</time_frame>
    <description>Steroid Burden is measured as milligrams (mg) of prednisone-equivalent administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Flares Per Patient-Year (Respectively and Overall) by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLEDAI Flare Index (SFI)</measure>
    <time_frame>Through Week 104</time_frame>
    <description>SELENA SLEDAI flare index defines (mild, moderate or severe) SLE flares using the SLEDAI-2K score, disease activity scenarios, treatment changes, and Physician's Global Assessment of Disease Activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of 50% Reduction of Tender or Swollen Lupus Joints (of Those Starting With Total ≥ 6 Affected Joints)</measure>
    <time_frame>Baseline of M19-130 (Week 0) Through Week 104</time_frame>
    <description>Achievement of 50% reduction in number of tender or swollen lupus joints of those starting with ≥ 6 affected joints as assessed by physical examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score, for those starting wtih CLASI ≥ 10 at M19-130 baseline</measure>
    <time_frame>Baseline of M19-130 (Week 0) Through Week 104</time_frame>
    <description>CLASI is an index used to assess cutaneous manifestations of SLE summarizing the activity of the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SLEDAI-2K</measure>
    <time_frame>Baseline of M19-130 (Week 0) Through Week 104</time_frame>
    <description>SLEDAI-2K is global SLE disease activity index that focuses on high-impact disease manifestations across the organ systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BILAG</measure>
    <time_frame>Baseline of M19-130 (Week 0) Through Week 104</time_frame>
    <description>BILAG is a global disease activity index based on the physician's intention to treat, focusing on changes in disease manifestations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)</measure>
    <time_frame>Baseline of M19-130 (Week 0) Through Week 96</time_frame>
    <description>FACIT-F is a patient-reported questionnaire developed to assess fatigue. The responses to the items on the FACIT-F questionnaire are each measured on a 5-point Likert scale. Items are scored on a 0 - 4 response scale, ranging from &quot;Not at all&quot; to &quot;Very much.&quot; All items are summed, with reverse scoring applied where appropriate (Items An5 &quot;I have energy&quot; and An7 &quot;I am able to do my usual activities&quot;). The sum creates a single fatigue score ranging from 0 - 52, with higher scores representing less fatigue or better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 36-Item Short Form Health Survey (SF-36)</measure>
    <time_frame>Baseline of M19-130 (Week 0) Through Week 96</time_frame>
    <description>SF-36 is a general Health Related Quality of Life (HRQoL) instrument which comprises 36 total questions targeting participant's functional health and well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lupus Quality of Life questionnaire (LupusQoL)</measure>
    <time_frame>Baseline of M19-130 (Week 0) Through Week 96</time_frame>
    <description>The Lupus Quality of Life (LupusQoL) is a disease-specific Health Related Quality of Life (HRQoL) patient reported outcome (PRO) instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Numerical Rating Scale (NRS)</measure>
    <time_frame>Baseline of M19-130 (Week 0) Through Week 96</time_frame>
    <description>The pain NRS scale is a single item questionnaire in which participants are asked to rate the overall pain level. The pain NRS scores range from 0 to 10, with higher scores indicating a higher level of pain.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Systemic Lupus Erythematosus (SLE)</condition>
  <arm_group>
    <arm_group_label>Part 1: Elsubrutinib Dose A and Upadacitinib Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Elsubrutinib Dose A and Upadacitinib Dose A once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Elsubrutinib Dose A and Upadacitinib Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Elsubrutinib Dose A and Upadacitinib Dose B QD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Elsubrutinib Dose A and Upadacitinib Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Elsubrutinib Dose A and Upadacitinib placebo QD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4: Elsubrutinib Placebo and Upadacitinib Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Elsubrutinib placebo and Upadacitinib Dose A QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elsubrutinib</intervention_name>
    <description>Oral; Capsule</description>
    <arm_group_label>Part 1: Elsubrutinib Dose A and Upadacitinib Dose A</arm_group_label>
    <arm_group_label>Part 2: Elsubrutinib Dose A and Upadacitinib Dose B</arm_group_label>
    <arm_group_label>Part 3: Elsubrutinib Dose A and Upadacitinib Placebo</arm_group_label>
    <other_name>ABBV-105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Elsubrutinib</intervention_name>
    <description>Oral; Capsule</description>
    <arm_group_label>Part 4: Elsubrutinib Placebo and Upadacitinib Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Oral; Tablet</description>
    <arm_group_label>Part 1: Elsubrutinib Dose A and Upadacitinib Dose A</arm_group_label>
    <arm_group_label>Part 2: Elsubrutinib Dose A and Upadacitinib Dose B</arm_group_label>
    <arm_group_label>Part 4: Elsubrutinib Placebo and Upadacitinib Dose A</arm_group_label>
    <other_name>ABT-494</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Upadacitinib</intervention_name>
    <description>Oral; Tablet</description>
    <arm_group_label>Part 3: Elsubrutinib Dose A and Upadacitinib Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed Study M19-130 (i.e., the preceding study of elsubrutinib, upadacitinib, and
             ABBV599 [elsubrutinib/upadacitinib] combination).

          -  On stable background treatment for SLE throughout the study.

        Exclusion Criteria:

          -  Active, chronic, or recurrent viral infection.

          -  Require vaccination with any live vaccine during study participation.

          -  Active tuberculosis (TB)

          -  History of gastrointestinal (GI) perforation, diverticulitis, or a significantly
             increased risk for GI perforation per investigator assessment.

          -  Participant require vaccination with live vaccine during study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center /ID# 222505</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>June DO, PC /ID# 221841</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>STAT Research, Inc. /ID# 221840</name>
      <address>
        <city>Vandalia</city>
        <state>Ohio</state>
        <zip>45377-9464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aprillus Asistencia e Investig /ID# 221890</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1046</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Interzonal Gral Agudos San Martin /ID# 221893</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1906</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CER Instituto Medico /ID# 223175</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>1878</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Respirar /ID# 223174</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <state>Ciuadad Autonoma De Buenos Aires</state>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado/Reuma /ID# 221888</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Ciuadad Autonoma De Buenos Aires</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto CAICI SRL /ID# 221892</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Militar Central Ciruj /ID# 222569</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Cordoba /ID# 221894</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigaciones Clin Tucuman /ID# 221889</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Enfermedades del Hígado y Aparato Digestivo /ID# 221891</name>
      <address>
        <city>Santa Fe</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum /ID# 221776</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum /ID# 221774</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht /ID# 221775</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mindful Medical Research /ID# 222513</name>
      <address>
        <city>San Juan</city>
        <zip>00918-3756</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario A Coruña - CHUAC /ID# 221993</name>
      <address>
        <city>A Coruña</city>
        <state>A Coruna</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Basurto /ID# 221999</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Galdakao /ID# 221996</name>
      <address>
        <city>Galdakao</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre /ID# 221994</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme /ID# 221997</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe /ID# 221998</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HUA - Txagorritxu /ID# 221992</name>
      <address>
        <city>Vitoria</city>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hosp /ID# 221747</name>
      <address>
        <city>Taichung City</city>
        <state>Taichung</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>ABBV-599</keyword>
  <keyword>ABBV-105</keyword>
  <keyword>ABT-494</keyword>
  <keyword>Elsubrutinib</keyword>
  <keyword>Upadacitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

